Lawrence True
Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (6)
Histopathology parameters are generally critical for the management of prostate cancer. Current practice is focussed on accuracy, precision, reproducibility, standardization and completeness of this data collection. This review discusses issues with this reporting practice and suggests a simpler alternative approach focussed on the clinical utility of pathology data and effective communication of the histopathology ‘message’. The principles of prostate cancer detection and management are significantly different from those of other cancers. These differences could have important implications for the histopathological diagnosis and reporting of prostate cancer. Management decisions are often based on pathology data from nontargeted prostate biopsies that are subject to significant sampling error, which precludes accurate determination of tumour size and grade. In contrast to other solid tumours, definitive tumour size, grade, and stage are available only in the minority of patients who have undergone complete tumour excision (radical prostatectomy). The availability of a serum marker (prostate‐specific antigen) for monitoring patients after prostate biopsy or prostatectomy would also significantly impact the clinical utility of histopathological data in these specimens. While it is necessary to report all mandatory data items, pathologists should focus their resources on data that are of clinical significance in an individual case. A pragmatic approach to prostate biopsy reporting with less emphasis on precise determination of tumour extent and grade is recommended.
Year:
2025
A and B, Representative micrographs of HER2 IHC staining in prostate cancer ( A ) and urothelial cancer ( B ) autopsy specimens. C, Number of patients with at least one tumor with the indicated HER2 IHC score, color coded by cancer type. D, Number of tumors across all patients with the indicated HER2 IHC score, color coded by cancer type. E and F, Percent of tumors expressing the indicated level of HER2 staining by IHC according to the tumor site sampled in prostate ( E ) and urothelial ( F ) cancer cohorts. Anatomic sites with only one representative tumor were excluded. PC, prostate cancer; UC, urothelial carcinoma.
Year:
2025
A and B, Box plots indicating the relationship between HER2 score with protein expression of key cell surface antigens as measured by IHC in ( A ) prostate cancer and ( B ) urothelial cancer.
Year:
2025
HER2 is an oncogenic driver in multiple cancers and a predictive biomarker for HER2-targeted therapies. Although HER2-directed therapies like fam-trastuzumab deruxtecan are approved for HER2-positive breast and other solid tumors, the landscape of HER2 expression in advanced prostate cancer and urothelial carcinoma remains inadequately characterized. We evaluated HER2 protein expression in metastatic prostate cancer and urothelial carcinoma using a validated IHC assay on tissue microarrays constructed from the University of Washington Tissue Acquisition Necropsy Program. HER2 expression was scored using standardized gastric cancer criteria. Genomic analysis of ERBB2 alterations was conducted on a subset of samples. HER2 expression heterogeneity and its relationship with other surface markers were also evaluated. In the prostate cancer cohort ( n = 52 patients, 1–19 tumors per patient), HER2 expression was low, with no 3+ expression observed and only five (10%) patients exhibiting 2+ expression. Low-level ERBB2 copy-number gains were observed in some tumors but did not correlate with HER2 protein expression ( P = 0.2). In urothelial carcinoma ( n = 20, 2–6 tumors per patient), HER2 expression was more frequent, with ≥2+ expression observed in six (30%) cases and 3+ expression observed in three (15%) cases in at least one tumor. Urothelial carcinoma samples showed less heterogeneity, with more consistent expression across metastases. HER2 overexpression is rare and heterogeneous in metastatic prostate cancer, limiting its utility as a therapeutic target. HER2 expression is more prevalent and uniform in urothelial carcinoma. These findings underscore the importance of comprehensive HER2 assessment in advanced urothelial carcinoma and suggest that success of HER2-directed therapies in prostate cancer will require careful case selection. Significance: This study demonstrates that HER2 is rarely overexpressed in metastatic prostate cancer but is more common and consistent in urothelial carcinoma. These findings highlight the need for HER2 testing in urothelial cancer and suggest that HER2-targeted therapies in prostate cancer will require careful patient selection.
Year:
2025
A and B, Mosaic plots indicating the relationship between ERBB2 genomic status as assessed by unadjusted copy number and HER2 IHC in ( A ) prostate and ( B ) urothelial cancers. C and D, Box plots indicating the relationship between HER2 RNA expression with ( C ) prostate and ( D ) urothelial cancers. PC, prostate cancer; UC, urothelial carcinoma.
Year:
2025
Lineage plasticity and histologic transformation from prostate adenocarcinoma to neuroendocrine (NE) prostate cancer (NEPC) occur in up to 15% to 20% of patients with castration-resistant prostate cancer (CRPC) as a mechanism of treatment resistance and are associated with aggressive disease and poor prognosis. NEPC tumors typically display small cell carcinoma morphology with loss of androgen receptor (AR) expression and gain of NE lineage markers. However, there is a spectrum of phenotypes that are observed during the lineage plasticity process, and the clinical significance of mixed histologies or those that co-express AR and NE markers or lack all markers is not well defined. Translational research studies investigating NEPC have used variable definitions, making clinical trial design challenging. In this manuscript, we discuss the diagnostic workup of metastatic biopsies to help guide the reproducible classification of phenotypic CRPC subtypes. We recommend classifying CRPC tumors based on histomorphology (adenocarcinoma, small cell carcinoma, poorly differentiated carcinoma, other morphologic variant, or mixed morphology) and IHC markers with a priority for AR, NK3 homeobox 1, insulinoma-associated protein 1, synaptophysin, and cell proliferation based on Ki-67 positivity, with additional markers to be considered based on the clinical context. Ultimately, a unified workup of metastatic CRPC biopsies can improve clinical trial design and eventually practice.
Year:
2025
Collaborators (22)
Rohit Mehra
University of Michigan Medical School
Hyun Jung Lee
Assistant Professor
Pusan National University Yangsan Hospital
Tamara L. Lotan
Professor
Johns Hopkins University
Jiaoti Huang
Professor and Chairman
Duke Medicine
Andrew C. Hsieh
Fred Hutchinson Cancer Research Center
Massimo Loda
Chair
Weill Cornell Medical College
Gavin Ha
Associate Professor
Fred Hutchinson Cancer Research Center
Michael Haffner
Fred Hutchinson Cancer Research Center
Sonali Arora
Fred Hutchinson Cancer Research Center
Heather H. Cheng
Professor
University of Washington
Chien-Kuang Ding
Assistant Professor
University of California, San Francisco
Petros Grivas
University of Washington
Radhika A Patel
Fred Hutch Cancer Center
Evan Y. Yu
University of Washington
Colm Morrissey
Research Professor
University of Washington
Mark A. Rubin
Professor
University of Bern
Michael T. Schweizer
University of Washington
Bruce Montgomery
University of Washington
Peter S. Nelson
Fred Hutchinson Cancer Research Center
Rahul Aggarwal
University of California
Maria Tretiakova
Professor
University of Washington
Jessica Hawley
Assistant Professor
University of Washington
Make your next move.
Prepare your application
Review drafts before you send them.